Browse our articles
New Alzheimer's drug slows cognitive decline by 35 per cent
Donanemab has been shown to reduce cognitive decline in people with early-stage Alzheimer’s disease.
On this page you can find news about Join Dementia Research, the latest advances in Dementia research and get inspiration from our blogs. Use the search bar to find something specific or browse different topics by clicking one of the topic buttons.
Donanemab has been shown to reduce cognitive decline in people with early-stage Alzheimer’s disease.
Join us on social:
Share your story
Email us:
Sign up for the Join Dementia Research Newsletter